Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Barnhart

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Drugs|December 25, 2008
The efficacy and safety of cilomilast in COPDStephen Rennard, Katharine Knobil, Klaus F Rabe, et al.
Chest|January 14, 2012
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialNicola A Hanania, Gregory Feldman, Wolfgang Zachgo, et al.
Annals of the American Thoracic Society|December 10, 2014
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPDCourtney Crim, Mark T Dransfield, Jean Bourbeau, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsMark T Dransfield, Jean Bourbeau, Paul W Jones, et al.
The New England Journal of Medicine|April 19, 2018
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPDDavid A Lipson, Frank Barnhart, Noushin Brealey, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Drugs|December 25, 2008
The efficacy and safety of cilomilast in COPDStephen Rennard, Katharine Knobil, Klaus F Rabe, et al.
Chest|January 14, 2012
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialNicola A Hanania, Gregory Feldman, Wolfgang Zachgo, et al.
Annals of the American Thoracic Society|December 10, 2014
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPDCourtney Crim, Mark T Dransfield, Jean Bourbeau, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsMark T Dransfield, Jean Bourbeau, Paul W Jones, et al.
The New England Journal of Medicine|April 19, 2018
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPDDavid A Lipson, Frank Barnhart, Noushin Brealey, et al.
Pageof 1